drugset / Trial / NCT04549012

Determination of Blood Loss After CS

NCT04549012

Phase 0 Unknown 130 enrolled Ain Shams University
RandomizedParallel-groupTriple-blindPrevention

Summary

Comparing betweeen tranexamic acid plus oxytocin and oxytocin alone in their efficacy in reducing blood loss following CS

Timeline

Start
2020-09
Primary completion
2021-09
Completion
2021-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tranexamic Acid Small molecule
Comparator Oxytocin Peptide

Indications

No indication recorded.